NEW YORK--(BUSINESS WIRE)--The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Lannett Company, Inc. (NYSE:LCI) between September 12, 2013 and November 3, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of Pennsylvania. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that Lannett violated securities laws by virtue of its failure to disclose that Lannett’s drug pricing relied on unsustainable pricing methodologies and that Lannett lacked effective internal controls concerning its drug pricing methodologies.
On July 16, 2014, Lannett revealed it had received interrogatories and a subpoena from the State of Connecticut Office of the Attorney General. By December 8, 2014, both the Company’s Senior Vice President of Sales and Marketing and the Company were served grand jury subpoenas. On November 4, 2016, Bloomberg reported that the Justice Department is conducting an antitrust investigation of over a dozen companies, including Lannett, to determine whether they unlawfully colluded with each other to fix generic drug prices.
If you suffered a loss in Lannett you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.